M12 Drug Interaction Studies

In August 2024, the U.S. Food and Drug Administration (FDA) released the M12 Drug Interaction Studies Guidance for Industry, developed in collaboration with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guidance aims to harmonize approaches in designing, conducting, and interpreting enzyme- or transporter-mediated in vitro and clinical drug-drug interaction (DDI) studies during the development of therapeutic products. U.S. Food and Drug Administration+1ich.org+1

Background

Patients are often prescribed multiple medications, leading to potential DDIs that can increase the risk of adverse effects or alter the efficacy of treatments. Recognizing the significance of DDIs in clinical practice, the FDA and ICH have provided this guidance to promote a consistent and efficient approach to DDI evaluation across different regulatory regions. U.S. Food and Drug Administration

Scope and Objectives

The M12 guidance focuses on pharmacokinetic interactions, particularly those mediated by metabolic enzymes and transporters. While primarily applicable to small chemical molecules, it also briefly addresses biologics, with an emphasis on monoclonal antibodies and antibody-drug conjugates. The guidance outlines recommendations for investigating interactions caused by inhibition or induction of enzymes or transporters, both in vitro and in vivo, and provides strategies for translating these findings into appropriate treatment recommendations. U.S. Food and Drug Administration+1ich.org+1

Key Recommendations

1. In Vitro Evaluation: The guidance recommends conducting in vitro studies to assess a drug’s potential as a substrate, inhibitor, or inducer of metabolic enzymes and transporters. These studies help identify possible interactions that may necessitate further clinical evaluation. FDA Access Data
2. Clinical Evaluation: If in vitro studies indicate a significant interaction potential, clinical DDI studies should be performed. These studies aim to quantify the impact of the investigational drug on the pharmacokinetics of other drugs and vice versa, informing dosing recommendations and risk mitigation strategies. U.S. Food and Drug Administration
3. Use of Modeling and Simulation: The guidance encourages the application of mathematical and mechanistic modeling approaches, such as physiologically based pharmacokinetic (PBPK) modeling, to predict clinical DDIs based on in vitro data. These models can support decision-making regarding the necessity and design of clinical DDI studies. U.S. Food and Drug Administration
4. Evaluation of Metabolites: The potential for drug metabolites to contribute to DDIs should be considered. In vitro studies can help determine whether metabolites warrant further clinical investigation based on their concentration and activity relative to the parent drug.

Implementation and Impact

By adopting the M12 guidance, regulatory agencies and pharmaceutical companies aim to streamline the DDI evaluation process, reduce redundancy, and ensure patient safety. A harmonized approach facilitates the efficient development of therapeutic products and enhances the ability to predict and manage potential DDIs in clinical practice. ich.orgU.S. Food and Drug Administration

Conclusion

The FDA’s adoption of the ICH M12 guidance underscores the commitment to global harmonization in drug development. By providing clear recommendations for evaluating DDIs, this guidance supports the development of safer and more effective therapeutic products, ultimately benefiting patients worldwide.

M12 Drug Interaction Studies – by Shudarsana Company